Abstract
Leflunomide is a selective inhibitor of de novo pyrimidine synthesis. In phase II and III clinical trials of active rheumatoid arthritis, leflunomide was shown to improve primary and secondary outcome...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have